The ALDH1B1 Knockout PaTu 8988t Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population in which the ALDH1B1 gene has been disrupted in the human PaTu 8988t cell line. This loss-of-function model is designed to ablate ALDH1B1 expression, enabling systematic investigation of its role in aldehyde metabolism, retinoic acid biosynthesis, and pancreatic cancer cell biology. The polyclonal format preserves a heterogeneous mixture of edited clones, reflecting population-level responses and minimizing artifacts associated with monoclonal selection. As a CRISPR/Cas9-mediated gene disruption, it provides a robust tool for studying ALDH1B1-dependent mechanisms in a well-characterized pancreatic ductal adenocarcinoma background.
The PaTu 8988t host cell line was established from a primary human pancreatic ductal adenocarcinoma tumor and serves as a widely used in vitro model of pancreatic cancer. These tumor-derived pancreatic epithelial cells recapitulate key features of ductal adenocarcinoma, including aberrant signaling networks and metabolic adaptations. PaTu 8988t cells are particularly suitable for functional studies due to their established growth characteristics, expression of pancreatic markers, and responsiveness to retinoic acid and oxidative stress modulators. The knockout model leverages this clinical relevant background to dissect ALDH1B1 contributions in a disease-appropriate context.
ALDH1B1 encodes a mitochondrial aldehyde dehydrogenase that irreversibly oxidizes retinaldehyde to retinoic acid, a critical morphogen regulating gene transcription. In the canonical retinoic acid biosynthesis pathway, retinol dehydrogenase 10 (RDH10) first generates retinaldehyde, which then serves as the substrate for ALDH1B1. The resulting retinoic acid activates nuclear retinoid acid receptors (RAR) and retinoid X receptors (RXR), forming heterodimers that directly modulate transcription of target genes, including cell cycle regulators and differentiation factors. ALDH1B1 is upregulated by NFE2L2 (NRF2) under oxidative stress and is regulated by RXR-mediated feedback, positioning it at the intersection of aldehyde detoxification and redox-sensitive signaling. Its interaction with the mitochondrial protein import machinery ensures proper localization, while broad aldehyde substrate specificity links it to alcohol metabolism and endogenous aldehyde clearance.
In pancreatic adenocarcinoma, ALDH1B1-mediated retinoic acid synthesis is thought to influence differentiation programs and cancer stem cell dynamics. Retinoic acid signaling can promote epithelial differentiation or, paradoxically, maintain stemness depending on context, making ALDH1B1 a key mediator of phenotypic plasticity. Additionally, ALDH1B1??s detoxification activity protects tumor cells from oxidative stress and reactive aldehyde accumulation, which are abundant in the tumor microenvironment. By eliminating ALDH1B1, this model allows dissection of its dual role in retinoic acid-dependent transcriptional regulation and cytoprotective aldehyde metabolism, providing insights into pancreatic cancer progression and therapeutic resistance.
The ALDH1B1 Knockout PaTu 8988t Polyclonal Cells support a broad range of research applications, including pancreatic cancer biology, retinoic acid signaling studies, and aldehyde detoxification research. Researchers can employ this model in functional assays such as ALDEFLUOR flow cytometry to measure aldehyde dehydrogenase activity, LC-MS for retinoic acid quantification, Western blotting and RT-qPCR for expression analysis, and cell-based readouts including colony formation, apoptosis, and migration studies. It is also well-suited for exploring drug metabolism and oxidative stress responses in a pancreatic cancer context. For additional information, please contact Ascent Research.
